AQST
Aquestive Therapeutics, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · NGM
$3.93
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
MODERATE
Data Confidence: 71.4%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$533M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-9.43
Based on estimated future earnings — lower means cheaper
Rev Growth
+65.7%
Year-over-year revenue change
Profit Margin
-137.1%
How much profit the company keeps from each dollar of revenue
ROE
N/A
Return on equity — how efficiently it uses shareholder money
Analyst Target
$8.89
+126% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 9 analysts covering this stock
About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

https://www.aquestive.com

Country: United States Employees: 147 Industry: Drug Manufacturers - Specialty & Generic
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
8.2% PASS
Debt must be below 33% of total assets
Cash Ratio
23.4% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKUP
Price trending up with increasing momentum
Sharpe Ratio
0.573
Good returns relative to risk taken
Kelly Fraction
0.0229
Modest edge detected — smaller position warranted
Calmar Ratio
0.244
Drawdown risk outweighs the returns — higher risk profile
Annual Return
14.9%
Historical annualised return based on price data
Max Drawdown
-60.8%
Largest peak-to-trough decline — the worst it has been
HMM State
BEAR
Statistical model detects bearish conditions
Days in State
6
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.50
Moves slightly more than the broader market
52W High
$7.55
48% below the year high
52W Low
$2.22
77% above the year low
Avg Volume
1,736,933
Average daily shares traded — higher means easier to buy and sell
Short Ratio
13.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
13.1%
Elevated short interest — bears are positioned against this
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.78
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.00
Conservative use of debt — low financial risk
Current Ratio
4.10
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
3.70
Like current ratio but excludes inventory — stricter test
Gross Margin
63.5%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-29.1%
Profit from core operations before interest and tax
Free Cash Flow
$-25,688,000
Negative — the business is spending more than it generates
Revenue (TTM)
$50M
Total revenue over the last 12 months
Net Income
$-68,911,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
9
Target High
$11.00
Target Median
$8.89
Target Low
$6.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-18 ZALEWSKI THOMAS A. Officer 100,000 —
2026-05-15 BARBER DANIEL R Chief Executive Officer 8,257 $35,413
2026-03-10 TOTH A ERNEST JR Chief Financial Officer 58,254 $243,094
2026-03-10 BARBER DANIEL R Chief Executive Officer 180,677 $753,965
2026-03-10 BOYD PETER E Officer 29,814 $124,414
2026-03-10 BRAENDER LORI J Officer 40,102 $167,346
2026-03-10 JUNG CASSIE Chief Operating Officer 45,791 $191,086
2026-03-10 KORCZYNSKI SHERRY Officer 15,741 $65,687
2026-03-10 CIOFFI MELINA Officer 25,311 $105,623
2026-03-09 TOTH A ERNEST JR Chief Financial Officer 95,000 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.